Open dataset · Orange Book Generic Competition · doi:10.5281/zenodo.24172675

Orange Book Generic Competition 2026: the open dataset behind the Generic Competition Check

Of 2,145 groups with a brand product listed as marketed, 1,083 have at least one generic listed as marketed and 1,062 do not. Where both a brand and a generic approval are dated (1,557 groups), the median interval from the first brand approval to the first generic approval is 9.9 years. Counts of the FDA's listing as of 12 November 2026. Version 1.0, published 13 November 2026. Every figure is reproducible from the files below; try it on your own case in the Generic Competition Check.
Brand groups in the Orange Book, by whether a generic is listed as marketed

A generic is listed as marketed

1,083 of 2,145 (50%)

No generic is listed as marketed

1,062 of 2,145 (50%)

What is in it?

The Orange Book's 48,865 product rows grouped by ingredient and dosage form (4,530 groups), with, for each group, the number of brand and generic products, how many are listed as marketed (not listed as discontinued), the number of distinct generic applicants, the first brand and first generic approval dates, and the patents and exclusivities still listed after the download date.

How should it be read?

"Marketed" means only that the Orange Book does not list a product as discontinued; it says nothing about stock, price or supply. A listed patent is the application holder's listing, not a ruling, and does not mean a generic is blocked.

What are the files?

The files are hosted on Zenodo with the DOI. Each has a SHA-256 hash, so a downloaded copy can be checked against it.

FileSizeSHA-256 (first 16)
README.md2 KBe4ce53badf1719bb
groups.csv390 KBc7167e43ea1aed81
products.csv6.2 MBf9b2470bee4920bf
patents.csv1.6 MBfe606adb0934d6dc
exclusivities.csv140 KB9e8f743928b76b1d
data.json790 bytes01daeb9d14530b7d
control-result.json332 bytes6ba7afb69a52c33b
PROTOCOL-GENERIC-COMPETITION-2026-11-12.md3 KB07cfc57c08db1305
protocol.sha256109 bytes66fa4c48c74e5411
code.zip25 KB4d0cfa9ca6f8a6b6
SHA256SUMS.txt902 bytes
  • groups.csv: one row per ingredient and dosage-form group. products.csv, patents.csv, exclusivities.csv: the rows behind it. data.json: the headline counts.
  • PROTOCOL-GENERIC-COMPETITION-2026-11-12.md and protocol.sha256: the method, frozen before any competition statistic was published.
  • control-result.json: the independent control. code.zip: the scripts that built these files.

How was it checked?

The method was frozen before any figure was published, on 12 November 2026; its SHA-256 hash begins 07cfc57c08db1305. A separate reader recomputed figures from the raw files: a random sample of 400 recomputed, 0 mismatches. Read how the Generic Competition Check was checked, including what the check found and what it does not cover.

What is not claimed?

That a generic will launch or on what date; that fewer makers means a higher price or a shortage; anything about price, supply or quality. Biologics are not in the Orange Book.

Has it been corrected?

None yet. Control: 400 sampled groups, 0 mismatches (the applicant-name rule is shared, see control-result.json).

How do I cite it?

Couey, V. W. (2026). Orange Book Generic Competition 2026: Generic Makers, First Generic Approvals and Listed Patents for 2,760 Ingredients (Version 1.0) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.24172675

Cite all versions: doi:10.5281/zenodo.24172674. This version: doi:10.5281/zenodo.24172675.

Where does the data come from?

US Food and Drug Administration, Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), data files downloaded 2026-11-12. Compiled by Vincent Wesley Couey (ORCID 0009-0005-6869-308X). Tool: https://omnirx.org/tools/generic-competition-check

Questions about this dataset

What is in the Orange Book Generic Competition dataset?

The Orange Book's 48,865 product rows grouped by ingredient and dosage form (4,530 groups), with, for each group, the number of brand and generic products, how many are listed as marketed (not listed as discontinued), the number of distinct generic applicants, the first brand and first generic approval dates, and the patents and exclusivities still listed after the download date.

Can I reuse it?

Yes. The compilation is licensed CC BY 4.0: reuse it with credit, citing the DOI (10.5281/zenodo.24172675). The underlying records keep the terms of their public source.

How was it checked?

The method was frozen and hashed before any figure was published (12 November 2026), and a separate reader recomputed figures from the raw files: a random sample of 400 recomputed, 0 mismatches. The full account is on the how-we-check page for the tool.

What does it not claim?

That a generic will launch or on what date; that fewer makers means a higher price or a shortage; anything about price, supply or quality. Biologics are not in the Orange Book.

Compiled by Vincent Wesley Couey (ORCID 0009-0005-6869-308X).